Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A deep-dive into the enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest concerns surrounding the ODYSSEY OUTCOMES trial of alirocumab post-ACS.
Read clinical reviewA detailed breakdown of the ODYSSEY OUTCOMES trial design, randomization, blinding, endpoint adjudication, and statistical framework that produced the 15% MACE reduction for alirocumab after acute coronary syndrome.
Read clinical reviewDeep-dive into long-term follow-up from the ODYSSEY OUTCOMES trial of alirocumab post-ACS, covering durability of MACE reduction, safety signals beyond the primary analysis, and what clinicians should know about sustained PCSK9 inhibition.
Read clinical reviewA deep-dive into the ODYSSEY OUTCOMES trial results for alirocumab post-ACS, covering primary and secondary endpoints, effect sizes, confidence intervals, time-course patterns, and subgroup analyses.
Read clinical reviewDeep-dive into pre-specified and post-hoc subgroup analyses from the ODYSSEY OUTCOMES trial of alirocumab post-ACS, examining differential MACE reduction by age, sex, BMI, baseline LDL-C, diabetes status, and more.
Read clinical reviewA deep-dive overview of the ODYSSEY OUTCOMES trial, explaining how alirocumab reduced major cardiovascular events in patients after acute coronary syndrome already on high-intensity statins.
Read clinical reviewA deep-dive into the ODYSSEY OUTCOMES trial examining how alirocumab's 15% MACE reduction in post-ACS patients on high-intensity statins reshaped guidelines, prescribing patterns, and real-world cardiology decision-making.
Read clinical review